| 신경계질환에서 면역글로불린정맥주사 |
|
|
|
|
| Intravenous immunoglobulins in neurological diseases |
|
Sa-Yoon Kang |
Correspondence:
Sa-Yoon Kang,
|
|
|
| Abstract |
|
Intravenous immunoglobulin (IVIg) has been used for nearly three decades, and is proving to be an efficient anti-inflammatory
and immunomodulatory treatment for a number of neurological diseases. Evidence from randomized controlled clinical trials has
established IVIg as a first-line therapy for chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, and
multifocal motor neuropathy and the efficacy and safety of IVIg treatment have been summarized in Cochrane systemic reviews.
Reports about successful IVIg treatment in other neurological condition exist, but its use remains investigational. IVIg is an
effective rescue therapy in exacerbations of myasthenia gravis and is beneficial as a second-line therapy for dermatomyositis
and stiff-person syndrome. IVIg has been tested in some neurodegenerative diseases, but a controlled study in Alzheimer
disease yielded disappointing results. Despite its widespread use and therapeutic success, the mechanisms of action of IVIg are
poorly understood. In addition, questions remain regarding the dose, timing and duration of IVIg treatment in neurological
diseases. This review highlights emerging data on the mechanisms of action of IVIg and practical guidelines on administration of
IVIg in diverse neurological diseases. |
| Key Words:
Evidence, Inflammatory, Intravenous immunoglobulin, Neurological disease, Treatment |
|
PDF Links
Full text via DOI
Download Citation
